JP2023071900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023071900A5 JP2023071900A5 JP2023034164A JP2023034164A JP2023071900A5 JP 2023071900 A5 JP2023071900 A5 JP 2023071900A5 JP 2023034164 A JP2023034164 A JP 2023034164A JP 2023034164 A JP2023034164 A JP 2023034164A JP 2023071900 A5 JP2023071900 A5 JP 2023071900A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disorder
- depression
- day
- mirtazapine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 4
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 4
- 230000001430 anti-depressive effect Effects 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 4
- 229940005513 antidepressants Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 206010042458 Suicidal ideation Diseases 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- -1 A composition Chemical compound 0.000 claims 1
- 206010001496 Agitated depression Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510801P | 2017-05-25 | 2017-05-25 | |
| US62/510,801 | 2017-05-25 | ||
| US201762518020P | 2017-06-12 | 2017-06-12 | |
| US62/518,020 | 2017-06-12 | ||
| JP2019564867A JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| PCT/IL2018/050570 WO2018216020A1 (en) | 2017-05-25 | 2018-05-24 | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564867A Division JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023071900A JP2023071900A (ja) | 2023-05-23 |
| JP2023071900A5 true JP2023071900A5 (https=) | 2023-06-20 |
| JP7585369B2 JP7585369B2 (ja) | 2024-11-18 |
Family
ID=64396350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564867A Active JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2019564988A Active JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
| JP2023034164A Active JP7585369B2 (ja) | 2017-05-25 | 2023-03-07 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2023077666A Active JP7537675B2 (ja) | 2017-05-25 | 2023-05-10 | 外傷後ストレス障害の治療用の製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564867A Active JP7308761B2 (ja) | 2017-05-25 | 2018-05-24 | Ｎｍｄａｒアンタゴニスト－応答性精神神経障害のための併用療法 |
| JP2019564988A Active JP7312116B2 (ja) | 2017-05-25 | 2018-05-24 | 外傷後ストレス障害の治療用の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077666A Active JP7537675B2 (ja) | 2017-05-25 | 2023-05-10 | 外傷後ストレス障害の治療用の製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10881665B2 (https=) |
| EP (2) | EP3630102B1 (https=) |
| JP (4) | JP7308761B2 (https=) |
| KR (2) | KR102654569B1 (https=) |
| CN (2) | CN110996947A (https=) |
| AU (2) | AU2018274765A1 (https=) |
| BR (2) | BR112019024817A2 (https=) |
| CA (2) | CA3064846A1 (https=) |
| IL (2) | IL270916B2 (https=) |
| MX (2) | MX394875B (https=) |
| RU (2) | RU2019143573A (https=) |
| WO (2) | WO2018216020A1 (https=) |
| ZA (2) | ZA201908617B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| CA3064846A1 (en) * | 2017-05-25 | 2018-11-29 | Glytech, Llc | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020092496A1 (en) * | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| CA3136418A1 (en) * | 2019-04-09 | 2020-10-15 | Vistagen Therapeutics, Inc. | Genetic variants associated with response to treatment of neurological disorders |
| KR20220164470A (ko) * | 2020-01-03 | 2022-12-13 | 유니버시티 오브 파도바 | 신경정신 장애 및 질병에 대한 질병-조절 치료제로서의 덱스트로메타돈 |
| CN115677519A (zh) * | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用 |
| CN113648320A (zh) * | 2021-08-16 | 2021-11-16 | 中国人民解放军军事科学院军事医学研究院 | 赛洛西宾抗创伤后应激障碍的医药用途 |
| WO2025004042A1 (en) * | 2023-06-29 | 2025-01-02 | The Sarah Herzog Memorial Hospital-Ezrath Nashim | Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| EP1073432B1 (en) * | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| US20050096396A1 (en) * | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| WO2005016319A2 (en) * | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| PT1587789E (pt) | 2003-01-16 | 2008-12-16 | Acadia Pharm Inc | Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| JP4996467B2 (ja) | 2004-09-27 | 2012-08-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| TW200631584A (en) * | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| CA2672494A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2826180C (en) * | 2011-01-31 | 2020-09-01 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2841063A2 (en) | 2012-04-27 | 2015-03-04 | Indiana University Research and Technology Corporation | Compositions and methods for treating ptsd and related diseases |
| SI3057595T1 (sl) * | 2013-10-18 | 2020-09-30 | Emalex Biosciences, Inc. | Spojeni benzazepini za zdravljenje jecljanja |
| WO2016049048A1 (en) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016061320A2 (en) * | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
| WO2017024129A1 (en) | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
| WO2017160813A1 (en) * | 2016-03-15 | 2017-09-21 | University Of The Sciences | Compositions and methods for treating compulsive-like behavior in a subject |
| CA3064846A1 (en) * | 2017-05-25 | 2018-11-29 | Glytech, Llc | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
-
2018
- 2018-05-24 CA CA3064846A patent/CA3064846A1/en active Pending
- 2018-05-24 CN CN201880048653.3A patent/CN110996947A/zh active Pending
- 2018-05-24 IL IL270916A patent/IL270916B2/en unknown
- 2018-05-24 EP EP18805411.8A patent/EP3630102B1/en active Active
- 2018-05-24 WO PCT/IL2018/050570 patent/WO2018216020A1/en not_active Ceased
- 2018-05-24 KR KR1020197038205A patent/KR102654569B1/ko active Active
- 2018-05-24 KR KR1020197038209A patent/KR102608479B1/ko active Active
- 2018-05-24 US US15/987,933 patent/US10881665B2/en active Active
- 2018-05-24 RU RU2019143573A patent/RU2019143573A/ru not_active Application Discontinuation
- 2018-05-24 EP EP18806042.0A patent/EP3630103B1/en active Active
- 2018-05-24 BR BR112019024817-0A patent/BR112019024817A2/pt active Search and Examination
- 2018-05-24 CN CN201880048442.XA patent/CN110996946A/zh active Pending
- 2018-05-24 WO PCT/IL2018/050567 patent/WO2018216018A1/en not_active Ceased
- 2018-05-24 AU AU2018274765A patent/AU2018274765A1/en not_active Abandoned
- 2018-05-24 MX MX2019014113A patent/MX394875B/es unknown
- 2018-05-24 MX MX2019014114A patent/MX394876B/es unknown
- 2018-05-24 JP JP2019564867A patent/JP7308761B2/ja active Active
- 2018-05-24 RU RU2019143572A patent/RU2019143572A/ru not_active Application Discontinuation
- 2018-05-24 US US15/987,941 patent/US20180338956A1/en not_active Abandoned
- 2018-05-24 IL IL270885A patent/IL270885B2/en unknown
- 2018-05-24 CA CA3065003A patent/CA3065003A1/en active Pending
- 2018-05-24 BR BR112019024802-1A patent/BR112019024802A2/pt unknown
- 2018-05-24 JP JP2019564988A patent/JP7312116B2/ja active Active
- 2018-05-24 AU AU2018274767A patent/AU2018274767A1/en not_active Abandoned
-
2019
- 2019-12-23 ZA ZA2019/08617A patent/ZA201908617B/en unknown
- 2019-12-23 ZA ZA2019/08616A patent/ZA201908616B/en unknown
-
2021
- 2021-01-01 US US17/139,999 patent/US11969431B2/en active Active
-
2022
- 2022-01-28 US US17/586,828 patent/US20220143041A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034164A patent/JP7585369B2/ja active Active
- 2023-05-10 JP JP2023077666A patent/JP7537675B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023071900A5 (https=) | ||
| RU2019143573A (ru) | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar | |
| Joffe et al. | Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine | |
| Rutgeerts | The limitations of corticosteroid therapy in Crohn’s disease | |
| JP2008510714A5 (https=) | ||
| Akpek et al. | A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease | |
| NZ756750A (en) | Methods and compositions comprising purified recombinant polypeptides | |
| JP2011157378A5 (https=) | ||
| JP2013504577A5 (https=) | ||
| CA2549467A1 (en) | A preventive agent for vasculitis | |
| JP2009518441A5 (https=) | ||
| JP2005516606A5 (https=) | ||
| JP2010500370A5 (https=) | ||
| Louis et al. | Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy | |
| JP2015524816A5 (https=) | ||
| Corren | Cytokine inhibition in severe asthma: current knowledge and future directions | |
| JP2017520562A5 (https=) | ||
| WO2020119424A1 (zh) | 一种含有sumo抑制剂的组合物及应用 | |
| WO2018051229A1 (en) | Novel regimes of fxr agonists | |
| Alderuccio et al. | Limited duration loncastuximab tesirine with rituximab induces high complete metabolic response rate in high-risk relapsed/refractory follicular lymphoma-a phase 2 study | |
| Komatsu et al. | Advancements in non-dopaminergic treatments for schizophrenia: a systematic review of pipeline developments | |
| JP2007506681A5 (https=) | ||
| Jiang et al. | The N-methyl-d-aspartate receptor hypothesis of ketamine’s antidepressant action: Evidence and controversies | |
| Takeda et al. | Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: open‐label pilot study | |
| de Groot | Targeting the complement system in ANCA-associated vasculitis management |